Ropeginterferon and Azacitidine for New TP53-Mutated Blood Cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs—ropeginterferon (an immune-boosting protein) and azacitidine (a cancer-fighting medicine)—in adults newly diagnosed with myelodysplastic syndrome or acute myeloid leukemia who have a specific genetic change (TP53 mutation). The goal is to help patients who cannot tolerate intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed with myelodysplastic syndrome or acute myeloid leukemia (blood and bone marrow cancer) with at least 10% cancer cells
- Have a confirmed TP53 genetic mutation (a specific type of gene change) in your cancer cells
- Be ineligible for intensive chemotherapy—either 60+ years old, or younger with significant heart, kidney, or lung problems
- Have adequate liver function (not severely damaged by the cancer or other causes)
- Agree to use effective birth control if you can become pregnant or father children, during and after treatment
- Not currently receiving other cancer treatments or investigational drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
This trial tests a study drug called ropeginterferon alfa-2b for people with certain blood cancers like CMML and MDS/MPN overlap syndromes. The goal is to see if it can help control the disease with fewer side effects.
Hear when a new Ropeginterferon trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.